A 50-year-old woman addicted to heroin: Review of treatment of heroin addiction

JAMA

Volumn 300, Issue 3, 2008, Pages 314-321

  O'Brien, Charles P ^a,b  

^a Education and Clinical Center

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; METHADONE; NALOXONE; NALTREXONE; OPIATE;

ADULT; ARTICLE; CASE REPORT; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETOXIFICATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HEROIN DEPENDENCE; HISTORY; HUMAN; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 47549115600     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.300.1.jrr80005     Document Type: Article

References (53)

1. Tyler J, Frith GH. Primary drug abuse among women: a national study. Drug Alcohol Depend. 1981;8(4):279-286.
2. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain. 2005;6(10):662-672.
3. Cohen E, Navaline H, Metzger D. High-risk behaviors for HIV: a comparison between crack-abusing and opioid-abusing African-American women. J Psychoactive Drugs. 1994;26(3):233-241.
4. Hausser D, Kuebler D. HIV-risk behaviour and prevention for injecting drug users: are women more at risk? Int Conf AIDS. 1998;12:389.
5. Wang EC. Methadone treatment during pregnancy. J Obstet Gynecol Neonatal Nurs. 1999;28(6):615-622.
6. Kaltenbach K, Finnegan LP. Developmental outcome of children born to methadone maintained women: a review of longitudinal studies. Neurobehav Toxicol Teratol. 1984;6(4):271-275.
7. Martell BA, O'Connor PG, Kerns RD, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med. 2007;146(2):116-127.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
9. O'Brien CP, Volkow N, Li TK. What's in a word? addiction versus dependence in DSM-V. Am J Psychiatry. 2006;163(5):764-765.
10. Musto DF. Opium, cocaine and marijuana in American history. Sci Am. 1991;265(1):40-47.
11. Campbell N. Discovering Addiction: The Science and Politics of Substance Abuse Research. Ann Arbor: University of Michigan Press; 2007:55.
12. Desmond DP, Maddux JF. Deaths among heroin users in and out of methadone treatment. J Mainten Addict. 2000;4(1):45-61.
13. Manski CF, Petrie CV, eds. Informing America's Policy on Illegal Drugs: What We Don't Know Keeps Hurting Us. Washington, DC: National Academies Press; 2001.
14. Hopfer CJ, Khuri E, Crowley T, Hooks A. Adolescent heroin use: a review of the descriptive and treatment literature. J Subst Abuse Treat. 2002;23(3):231-237.
15. Cicero TJ, Adams EH, Geller A, et al. A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend. 1999;57(1):7-22.
16. Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade - a medical technique for stopping heroin use by addicts. Arch Intern Med. 1966;118(4):304-309.
17. Ribeiro Do Couto B, Aguilar MA, Manzanedo C, Rodriguez-Arias M, Minarro J. Reinstatement of morphine-induced conditioned place preference in mice by priming injections. Neural Plast. 2003;10(4):279-290.
18. Mark TL, Woody G, Juday T, Kleber H. The economic costs of heroin addiction in the United States. Drug Alcohol Depend. 2001;61(2):195-206.
19. Van Den Brink W, Hendriks VM, Van Ree JM. Medical co-prescription of heroin to chronic, treatment-resistant methadone patients in the Netherlands. J Drug Issues. 1999;29(3):587-608.
20. Rothenberg S, Schottenfeld S, Meyer RE, Krauss B, Gross K. Performance differences between addicts and non-addicts. Psychopharmacology (Berl). 1977;52(3):299-306.
21. Specka M, Finkbeiner T, Lodemann E, Leifert K, Kluwig J, Gastpar M. Cognitive-motor performance of methadone-maintained patients. Eur Addict Res. 2000;6(1):8-19.
22. Zanis DA, Woody GA. One-year mortality rates following methadone treatment discharge. Drug Alcohol Depend. 1998;52(3):257-260.
23. Barnett PG, Hui SS. The cost-effectiveness of methadone maintenance. Mt Sinai J Med. 2000;67(5-6):365-374.
24. Peng PW, Tumber PS, Gourlay D. Perioperative pain management of patients on methadone therapy. Can J Anaesth. 2005;52(5):513-523.
25. Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol. 1994;2:244-268.
26. O'Brien C. Drug addiction and drug abuse. In: Brunton L, Lazo J, Parker K, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2006:607-627.
27. Hser YI, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001;58(5):503-508.
28. Stimmel B, Goldberg J, Rotkopf E, Cohen M. Ability to remain abstinent after methadone detoxification. JAMA. 1977;237(12):1216-1220.
29. O'Brien CP. Opiate detoxification: what are the goals? Addiction. 2005;100(8):1035.
30. Amato L, Davoli M, Minozzi S, Ali R, Ferri M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev. 2005;(3):CD003409.
31. O'Brien CP, Testa T, O'Brien TJ, Brady JP, Wells B. Conditioned narcotic withdrawal in humans. Science. 1977;195(4282):1000-1002.
32. Mintz J, Goldschmidt J, O'Hare K, O'Brien CP. Double-blind detoxification of methadone maintenance patients. Int J Addict. 1975;10(5):815-824.
33. Kakko J, Gronbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry. 2007;164(5):797-803.
34. Doran CM, Shanahan M, Mattick RP, Ali R, White J, Bell J. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend. 2003;71(3):295-302.
35. Cornish JW, Metzger D, Woody GE, et al. Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat. 1997;14(6):529-534.
36. Bale RN, Zarcone VP, Van Stone WW, Kuldau JM, Engelsing TM, Elashoff RM. Three therapeutic communities: a prospective controlled study of narcotic addiction treatment: process and two-year follow-up results. Arch Gen Psychiatry. 1984;41(2):185-191.
37. Bale RN, Van Stone WW, Kuldau JM, et al. Therapeutic communities vs methadone maintenance: a prospective controlled study of narcotic addiction treatment: design and one-year follow-up. Arch Gen Psychiatry. 1980;37(2):179-193.
38. Caldiero RM, Parran TV Jr, Adelman CL, Piche B. Inpatient initiation of buprenorphine maintenance vs. detoxification: can retention of opioid-dependent patients in outpatient counseling be improved? Am J Addict. 2006;15(1):1-7.
39. O'Brien CP, Woody G, McLellan AT. Modern treatment of substance abuse. Drug Alcohol Depend. 1983;11(1):95-99.
40. Collins ED, Kleber HD, Whittington RA, Heitler NE. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA. 2005;294(8):903-913.
41. Kreek MJ. Rationale for maintenance pharmacotherapy of opiate dependence. In: O'Brien CP, Jaffe J, eds. Addictive States. New York, NY: Raven Press; 1992:205-230.
42. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267(20):2750-2755.
43. Drug Addiction Treatment Act of 2000. http://frwebgate.access.gpo.gov/ cgi-bin/getdoc.cgi?dbname=106_cong_public_laws&docid=f:publ310.106. Accessed June 16, 2008.
44. Congressman Cummings applauds signing of the Office of National Drug Control Policy (ONDCP) reauthorization, and Dawson Family Community Protection Act into law. January 5, 2007. http://www.house.gov/cummings/press/07jan05b.htm. Accessed June 19, 2008.
45. Judson BA, Goldstein A. Naltrexone treatment of heroin addiction: one-year follow-up. Drug Alcohol Depend. 1984;13(4):357-365.
46. O'Brien CP, Woody GE, McLellan AT. A new tool in the treatment of impaired physicians. Phila Med. 1986;82:442-446.
47. Garbutt JC, Kranzler H, O'Malley S, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized clinical trial. JAMA. 2005;293(13):1617-1625.
48. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63(2):210-218.
49. Gossop M, Stewart D, Marsden J. Attendance at Narcotics Anonymous and Alcoholics Anonymous meetings, frequency of attendance and substance use outcomes after residential treatment for drug dependence: a 5-year follow-up study. Addiction. 2008;103(1):119-125.
50. Suboxone certification. http://www.suboxone.com/hcp/certification. Accessed June 17, 2008.
51. Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64(5):566-576.
52. Sayers SL, Campbell EC, Kondrich J, et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis. 2005;193(6):379-386.
53. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689-1695.